Recombinant Cytokines Drug Market

Cytokines are a broad and loose category of small proteins (~5?20 kDa) that are important in cell signaling. Cytokines are peptides, and cannot cross the lipid bilayer of cells to enter the cytoplasm. Cytokines have been shown to be involved in autocrine signaling, paracrine signaling and endocrine signaling as immunomodulating agents. Their definite distinction from hormones is still part of ongoing research. Cytokines include chemokines, interferons, interleukins, lymphokines, and tumour necrosis factors, but generally not hormones or growth factors (despite some overlap in the terminology). Cytokines are produced by a broad range of cells, including immune cells like macrophages, B lymphocytes, T lymphocytes and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells; a given cytokine may be produced by more than one type of cell.

Some cytokines have been developed into protein therapeutics using recombinant DNA technology. Recombinant cytokines being used as drugs as of 2014 include:
Bone morphogenetic protein (BMP), used to treat bone-related conditions
Erythropoietin (EPO), used to treat anemia
Granulocyte colony-stimulating factor (G-CSF), used to treat neutropenia in cancer patients
Granulocyte macrophage colony-stimulating factor (GM-CSF), used to treat neutropenia and fungal infections in cancer patients
Interferon alfa, used to treat hepatitis C and multiple sclerosis
Interferon beta, used to treat multiple sclerosis
Interleukin 2 (IL-2), used to treat cancer.
Interleukin 11 (IL-11), used to treat thrombocytopenia in cancer patients.
Interferon gamma is used to treat chronic granulomatous disease and osteopetrosis
Recombinant Cytokines Drug Market aims to provide a comprehensive presentation of the global market for Recombinant Cytokines Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Cytokines Drug. Recombinant Cytokines Drug Market contains market size and forecasts of Recombinant Cytokines Drug in global, including the following market information:
Global Recombinant Cytokines Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Recombinant Cytokines Drug Market Sales, 2018-2023, 2024-2029, (KG)
Global top five Recombinant Cytokines Drug companies in 2022 (%)
The global Recombinant Cytokines Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Interferon Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Recombinant Cytokines Drug include Roche, Merck, Bayer, Biogen Idec, Gensci, Huaxin, Triprime, Sinovac and Zhaoke, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Cytokines Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Cytokines Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Cytokines Drug Market Segment Percentages, by Type, 2022 (%)
Interferon
Recombinant Human Granulocyte Colony-Stimulating
Erythropoietin (EPO)
Recombinant Human Thrombopoietin
Others
Global Recombinant Cytokines Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Cytokines Drug Market Segment Percentages, by Application, 2022 (%)
Hepatitis B
Hepatitis C
Multiple Sclerosis
Tumor Therapy
Wound Healing
Others
Global Recombinant Cytokines Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (KG)
Global Recombinant Cytokines Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Cytokines Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Recombinant Cytokines Drug revenues share in global market, 2022 (%)
Key companies Recombinant Cytokines Drug sales in global market, 2018-2023 (Estimated), (KG)
Key companies Recombinant Cytokines Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Merck
Bayer
Biogen Idec
Gensci
Huaxin
Triprime
Sinovac
Zhaoke
Kawin
Abcam plc
R&D Systems
Thermo Fisher Scientific
BioLegend
Invitrogen
OriGene
Biorbyt
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Cytokines Drug, market overview.
Chapter 2: Global Recombinant Cytokines Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Cytokines Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Cytokines Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Cytokines Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.